Meaningful Use Gives HIT Execs Chance For Improvement
Health IT (HIT) will most likely achieve its most significant improvements over the next 12 months by meeting meaningful use, according to a survey conducted among HIT Senior Management and Executives by Stoltenberg Consulting at the recent HIMSS13 conference in New Orleans, LA.
While a majority of respondents (35 percent) placed meaningful use in the top spot, 19 percent of respondents identified the areas in which HIT will achieve the most significant improvements as health information exchange, clinical Integration and mobile health, respectively.
“Those hospitals that can successfully achieve meaningful use implementation will benefit greatly from the resulting updated systems, enhanced processes and increased data security,” said Shane Pilcher, Vice President of Stoltenberg Consulting. He cautioned that “organizations still need to overcome the hurdles inherent in meeting meaningful use however, before they can reap the benefits of it.”
Survey respondents identified the three greatest challenges in fulfilling meaningful use requirements in their organizations as confusion and/or ambiguity about the regulation itself (29 precent); competing health IT projects (23 percent) and lack of resources such as funding, IT skill, talent and time (17 percent).
“While these challenges certainly impact hospitals of all sizes, they are particularly daunting for rural and community hospitals,” noted Pilcher. “To have the best chance of meeting meaningful use, smaller hospitals should develop an effective plan of action that unites IT, internal administration and clinical providers.”
Read Related Articles On Healthcare Global
- Health Execs Are Increasingly Relying On Technology
- Tips For Developing A Hospital mHealth Strategy
- Bridging The Healthcare IT Skills Gap
Emerging Health IT Trends
The Stoltenberg survey also uncovered the top three issues likely to dominate HIT dialogue for the remainder of 2013: Health Information Exchange (62 percent); Mobile Health (58 percent) and Clinical Analytics (54 percent).
Pilcher stated that “like meaningful use, Health Information Exchange, mobile health and clinical analytics can all ultimately have a positive impact on an organization's bottom line in addition to the ability to improve healthcare delivery, but they also require the type of extensive knowledge, expertise and experience in healthcare IT that might be best accessed through a qualified HIT services provider.”
In fact, according to the Stoltenberg survey, the issues or problems that HIT executives would most likely consult with a specialized IT consulting firm to resolve are: ICD-10 (25 percent); meaningful use (25 percent); clinical and business intelligence (23 percent); cloud computing (21 percent); and CPOE/clinical systems implementation (20 percent).
Survey respondents included HIT management, physicians and clinicians representing healthcare providers and payers, government agencies and HIT services vendors, among others.
About Stoltenberg Consulting
Founded in 1995, Pittsburgh-based Stoltenberg Consulting Inc. creates an environment for success by working with healthcare organizations to provide a variety of services including project management, implementation support and integration between systems. Members of the Stoltenberg Consulting team are consultants with extensive experience in both financial and clinical systems, averaging more than 15 years of direct on-site hospital experience. Stoltenberg Consulting has grown rapidly to serve a client base of more than 200 preeminent healthcare organizations throughout the United States providing services for Siemens (Approved Partner), Epic (Preferred Partner), Cerner, McKesson, Meditech, NextGen, Allscripts and Zynx customers. Stoltenberg was named #1 in the Staff Augmentation category by the 2012 Best in KLAS Awards: Software & Services report. For more information call 1-888-724-1326 or visit www.stoltenberg.com.
The challenges to vaccine distribution affecting everyone
While it is comforting to know that vaccines against COVID-19 are showing remarkable efficacy, the world still faces intractable challenges with vaccine distribution. Specifically, the sheer number of vaccines required and the complexity of global supply chains are sure to present problems we have neither experienced nor even imagined.
Current projections estimate that we could need 12-15 billion doses of vaccine, but the largest vaccine manufacturers produce less than half this volume in a year. To understand the scale of the problem, imagine stacking one billion pennies – you would have a stack that is 950 miles high. Now, think of that times ten. This is a massive problem that one nation can’t solve alone.
Even if we have a vaccine – can we make enough? Based on current projections, Pfizer expects to produce up to 1.3 billion doses this year. Moderna is working to expand its capacity to one billion units this year. Serum Institute of India, the world’s largest vaccine producer, is likely to produce 60% of the 3 billion doses committed by AstraZeneca, Johnson & Johnson and Sanofi. This leaves us about 7 billion doses short.
Expanding vaccine production for most regions in the world is complicated and time-consuming. Unlike many traditional manufacturing operations that can expand relatively quickly and with limited regulation, pharmaceutical production must meet current good manufacturing practice (CGMP) guidelines. So, not only does it take time to transition from R&D to commercial manufacturing, but it could also take an additional six months to achieve CGMP certification.
The problem becomes even more complex when considering the co-products required. Glass vials and syringes are just two of the most essential co-products needed to produce a vaccine. Last year, before COVID-19, global demand for glass vials was 12 billion. Even if it is safe to dispense ten doses per vial, there is certain to be significant pressure on world supply of the materials needed to package and distribute a vaccine.
It is imperative drug manufacturers and their raw material suppliers have clear visibility of production plans and raw material availability if there is any hope of optimizing scarce resources and maximising production yield.
It is widely known by now that temperature is a critical factor for the COVID-19 vaccine. Even the regions with the most developed logistics infrastructures and resources needed to support a cold-chain network are sure to struggle with distribution.
For the United States alone, State and local health agencies have determined distribution costs will exceed $8.4 billion, including $3 billion for workforce recruitment and training; $1.2 billion for cold-chain, $1 billion vaccination sites and $0.5 billion IT upgrades.
The complexity of the problem increases further when considering countries such as India that do not have cold-chain logistics networks that meet vaccine requirements. Despite India’s network of 28,000 cold-chain units, none are capable of transporting vaccines below -25°Celsius. While India’s Serum Institute has licensed to manufacture AstraZeneca’s vaccine, which can reportedly be stored in standard refrigerated environments, even a regular vaccine cold chain poses major challenges.
Furthermore, security will undoubtedly become a significant concern that global authorities must address with a coordinated solution. According to the Pharmaceutical Security Institute, theft and counterfeiting of pharmaceutical products rose nearly 70% over the past five years. As with any valuable and scarce product, counterfeits will emerge. Suppliers and producers are actively working on innovative approaches to limit black-market interference. Corning, for example, is equipping vials with black-light verification to curb counterfeiting.
Clearly, this is a global problem that will require an unprecedented level of collaboration and coordination.
Disconnected information systems
While it is unreasonable to expect every country around the world will suddenly adopt a standard technology that would provide immediate, accurate and available information for everyone, it is not unreasonable to think that we can align on a standard taxonomy that can serve as a Rosetta Stone for collaboration.
A shared view of the situation (inventory, raw materials, delivery, defects) will provide every nation with the necessary information to make life-saving decisions, such as resource pooling, stock allocations and population coverage.
By allowing one central authority, such as the World Health Organization, to organize and align global leaders to a single collaboration standard, such as GS1, and a standard sharing protocol, such as DSCSA, then every supply chain participant will have the ability to predict, plan and execute in a way that maximises global health.
Political influence and social equality
As if we don’t have enough stress and churn in today’s geopolitical environment, we must now include the challenge of “vaccine nationalism.” While this might not appear to be a supply chain problem, per se, it is a critical challenge that will hinge on supply chain capabilities.
In response to the critical supply issues the world experienced with SARS-CoV-2, the World Health Organization, Gavi, the Vaccine Alliance and the Coalition for Epidemic Preparedness Innovations (CEPI) formed Covax: a coalition dedicated to equitable distribution of 2 billion doses of approved vaccines to its 172 member countries. Covax is currently facilitating a purchasing pool and has made commitments to buy massive quantities of approved vaccines when they become available.
However, several political powerhouse countries, such as the United States and Russia, are not participating. Instead, they are striking bilateral deals with drug manufacturers – essentially, competing with the rest of the world to secure a national supply. Allocating scarce resources is never easy, but when availability could mean the difference between life and death, it becomes almost impossible.
Global production, distribution and social equality present dependent yet conflicting realities that will demand global supply chains provide complete transparency and an immutable chain of custody imperative to vaccine distribution.
The technology is available today – we just need to use it. We have the ability to track every batch, pallet, box, vile and dose along the supply chain. We have the ability to know with absolute certainty that the vaccine is approved, where and when it was manufactured, how it was handled and whether it was compromised at any point in the supply chain. Modern blockchain technologies should be applied so that every nation, institution, regulator, doctor and patient can have confidence in knowing that they are making an impact in eradicating COVID-19.